Mirador Capital Partners LP Invests $3.01 Million in Sarepta Therapeutics, Inc. $SRPT

Mirador Capital Partners LP purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 139,982 shares of the biotechnology company’s stock, valued at approximately $3,012,000. Mirador Capital Partners LP owned about 0.13% of Sarepta Therapeutics at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. iSAM Funds UK Ltd bought a new position in Sarepta Therapeutics during the 3rd quarter worth $25,000. Ancora Advisors LLC boosted its position in shares of Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,000 shares during the period. Byrne Asset Management LLC bought a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $33,000. Allworth Financial LP grew its stake in shares of Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC grew its stake in shares of Sarepta Therapeutics by 165.3% in the third quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,256 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SRPT. Weiss Ratings reiterated a “sell (d)” rating on shares of Sarepta Therapeutics in a research note on Monday, December 29th. Citigroup increased their target price on shares of Sarepta Therapeutics from $9.00 to $13.00 and gave the stock a “sell” rating in a research report on Thursday. Loop Capital set a $25.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 3rd. Needham & Company LLC reiterated an “underperform” rating on shares of Sarepta Therapeutics in a research report on Thursday. Finally, Oppenheimer reiterated an “outperform” rating and issued a $37.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, March 19th. Nine equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the company’s stock. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Hold” and an average target price of $32.30.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $19.97 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $72.05. The stock has a market capitalization of $2.10 billion, a P/E ratio of -2.37, a price-to-earnings-growth ratio of 0.34 and a beta of 0.42. The stock has a fifty day moving average of $18.69 and a 200-day moving average of $19.99.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The business had revenue of $442.93 million during the quarter, compared to analyst estimates of $390.95 million. During the same period last year, the business earned $1.90 earnings per share. The business’s quarterly revenue was down 32.7% compared to the same quarter last year. On average, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Key Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Early siRNA Phase 1/2 data (SRP‑1001, SRP‑1003) impressed investors — strong target knockdown, safety and muscle delivery signals sparked the share rally and lifted sentiment on Sarepta. SRPT Stock Surges on Promising Early Results From siRNA Programs
• Positive Sentiment: Options flow has been very bullish — large volume of call purchases suggests traders are positioning for further upside or continued momentum. Investors Buy Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT)
• Positive Sentiment: At least one major shop (reported coverage) raised its price target after the data, which helped validate the clinical news and contributed to the rally. Sarepta (SRPT) Skyrockets 35% on Morgan Stanley PT Hike, Stellar Trial Results
• Neutral Sentiment: Analyst consensus remains cautious/neutral overall — the stock’s average rating is a “Hold,” reflecting mixed views despite the clinical upside. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Average Rating of “Hold” from Brokerages
• Neutral Sentiment: Valuation and longer‑term upside are being reassessed: several writeups model potential upside but note the one‑day rebound and remaining execution risks. Assessing Sarepta Therapeutics (SRPT) Valuation After Early siRNA Trial Results
• Negative Sentiment: Some sell/underperform stances persist — Citigroup raised its PT but kept a sell rating, and Needham reaffirmed underperform, highlighting continued skepticism among parts of the sell‑side. These views can cap rallies if the broader data set or guidance don’t follow through. Brokerage Notes (Citigroup/Needham)
• Negative Sentiment: Cautious takeaways from analysts/commentators emphasize the data are early and limited; some warn it’s too soon to extrapolate material commercial potential, which could lead to profit‑taking or volatility. Sarepta Therapeutics: It’s Too Early To Get Excited About siRNA Data

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Stephen Mayo sold 7,239 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the sale, the director directly owned 1,765 shares in the company, valued at approximately $30,040.30. This trade represents a 80.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 7.60% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.